Using radiofrequency ablation to boost immune response in colorectal liver cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the use of radiofrequency ablation (RFA) as a supplementary treatment to enhance the immune response in patients undergoing surgery for colorectal liver metastases. The hypothesis is that RFA will partially destroy the tumors, making hidden cancer antigens visible to the immune system, which may improve survival rates by reducing the risk of recurrence. A total of 220 patients with colorectal liver metastases will be enrolled and randomized to assess the effectiveness of this approach. The study aims to provide insights into how RFA can be utilized to stimulate immunogenicity and improve patient outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with colorectal liver metastases planned for resection
* At least one tumor size \>=3cm
* Performance status 0-1

Exclusion Criteria:

* Liver cirrhosis
* Extrahepatic metastases that can not be addressed curatively
* Other malignant diseases within 5 years prior to diagnosis
* Prior RFA treatment

Where it's running

• Aarhus University Hospital, Department of Surgery
  Aarhus, Denmark Recruiting

Study contacts

• Principal investigator: Frank V Mortensen, MD, DMSc — Aarhus University Hospital
• Study coordinator: Jakob Kirkegård, MD, PhD
• Email: jakob.kirkegaard@auh.rm.dk
• Phone: +4524995027

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Can hepatic artery infusion chemotherapy enable liver surgery for colorectal cancer that has spread to the liver?

  This study tests whether hepatic artery infusion chemotherapy plus standard chemotherapy can make some inoperable colorectal liver metastases operable in patients.

  Recruiting Phase 2 Sunnybrook Health Sciences Centre · Toronto, Ontario · NCT07764497

• Electrochemotherapy for unresectable visceral tumors including liver metastases

  This will try electrochemotherapy with bleomycin in adults who have unresectable primary or metastatic visceral tumors, such as liver metastases.

  Recruiting Istituto Oncologico Veneto IRCCS · Padova · NCT06753136

• Evaluating a new immuno-adjuvant for colorectal liver metastases after ablation treatments

  This study is testing a new treatment called IP-001 to see if it can boost the immune response and help people with colorectal liver metastases feel better after they have undergone ablation therapies.

  Recruiting Phase 1/2 Amsterdam UMC, location VUmc · Amsterdam, North Holland · NCT06630624

• Comparing simultaneous and staged surgery for colorectal cancer with liver metastases

  This study is testing whether doing surgery for colon cancer and liver tumors at the same time or in separate stages is better for patients in terms of recovery and overall health.

  Recruiting Oslo University Hospital · Oslo · NCT06200831

• Comparing two treatments for colorectal liver metastases

  This study is testing whether a new treatment called irreversible electroporation works better than stereotactic body radiotherapy for people with hard-to-treat colorectal cancer that has spread to the liver.

  Recruiting Phase 2/3 Amsterdam UMC, location VUmc · Amsterdam, North Holland · NCT06185556

• Using AI to improve treatment for liver tumors

  This study is testing whether using artificial intelligence can help doctors choose the best treatments and predict outcomes for patients with liver tumors undergoing thermal ablation.

  Recruiting Leiden University Medical Center · Leiden · NCT06179602

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.